TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib
TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib
复制标题
基于TMT的蛋白质组学分析双氢青蒿素联合索拉非尼的抗肝癌作用
DOI：
10.1016/j.biopha.2020.109862
复制
发表时间：
2020-06-01
影响因子：
7.5
通讯作者：
Liu, Tianhua
中科院分区：
文献类型：
--
作者：
Hou, Chunying;Guo, Dongqing;Liu, Tianhua
肝细胞癌（HCC）作为主要的原发性肝癌，是世界范围内发病率最高、死亡率最高的恶性疾病之一。已有研究表明，青蒿素的半合成衍生物双氢青蒿素（DHA）具有抗hcc的活性。多激酶抑制剂索拉非尼已被批准用于治疗HCC。然而，DHA联合索拉非尼抗hcc的疗效尚未见报道。在本研究中，我们证实DHA与索拉非尼联合使用比单独使用具有显著增强的抗hcc疗效。串联质量标签（TMT）肽标记结合LC-MS/MS对对照组、DHA组、索拉非尼组和DHA +索拉非尼组的蛋白质进行定量。总共有532,426,628个差异表达蛋白(fold change >1.20或
Hepatocellular carcinoma (HCC), as the major primary liver cancer, is one of the most prevalent malignant diseases with a high mortality rate worldwide. Prior studies have demonstrated that dihydroartemisinin (DHA), the semisynthetic derivative of artemisinin, possesses anti-HCC activity. The multikinase inhibitor sorafenib has been approved for the treatment of HCC. However, the anti-HCC efficacy of DHA combined with sorafenib has not been reported. In this study, we confirmed the significantly enhanced anti-HCC efficacy of DHA in combination with sorafenib compared with that of each agent alone. Tandem Mass Tag (TMT) peptide labeling coupled with LC-MS/MS was used to quantify the proteins from the control, DHA, sorafenib, and DHA + sorafenib groups. In total, 532, 426, 628 differentially expressed proteins (fold change >1.20 or